Welcome to our dedicated page for Lucid Diagnostics SEC filings (Ticker: LUCD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Lucid Diagnostics Inc. (NASDAQ: LUCD), a commercial-stage, cancer prevention medical diagnostics company focused on esophageal precancer detection in patients with gastroesophageal reflux disease (GERD). Through these filings, investors can review the company’s official disclosures on financial performance, capital structure, and material corporate events.
Current reports on Form 8-K document significant events such as quarterly financial results, public offerings of common stock, and board appointments. For example, Lucid has filed 8-Ks to furnish press releases announcing financial results for quarters ended June 30 and September 30, 2025, to report the entry into and closing of an underwritten public offering of common stock under a shelf registration statement on Form S-3, and to disclose the appointment of a new director designated by holders of its convertible secured promissory notes.
Periodic reports such as Forms 10-Q and 10-K, referenced in Lucid’s press releases and 8-K filings, contain detailed financial statements, management’s discussion and analysis, and additional information about its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device business. These documents explain how the company reports EsoGuard-related revenues, operating expenses, and non-GAAP measures such as EBITDA and non-GAAP adjusted loss.
Investors can also find information on securities offerings and agreements in Lucid’s filings. An 8-K dated September 10, 2025 describes an underwriting agreement for an underwritten public offering of common stock, including the number of shares, public offering price, underwriting discount, and use of proceeds for working capital and general corporate purposes. A subsequent 8-K dated September 11, 2025 reports the closing of that offering and the expected net proceeds.
Stock Titan’s interface surfaces these SEC filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the significance of each filing. Real-time updates from the EDGAR system ensure that new 8-Ks, 10-Qs, 10-Ks, and other forms are added as they are filed, while Form 4 and related insider transaction reports, when available, can be reviewed to analyze trading activity by Lucid’s officers, directors, or significant shareholders.
Lucid Diagnostics Inc. (LUCD) reported an insider grant to director John R. Palumbo: an employee stock option to buy 215,000 shares of common stock at an exercise price of $1.03 per share. The option was granted on 10/06/2025, is exercisable through 10/06/2035, and is shown as directly owned following the grant. Vesting begins with one third vesting on 6/30/2026, then the remainder vests in eight equal quarterly installments from 9/30/2026 through 6/30/2028. The grant was made under the company's Amended and Restated 2018 Long-Term Incentive Equity Plan.
John R. Palumbo, a director of Lucid Diagnostics Inc. (LUCD), filed an Initial Statement of Beneficial Ownership reporting direct ownership of 47,857 shares of common stock. The transaction date requiring the filing is 09/22/2025. The Form 3 was signed by Michael A. Gordon by power of attorney on 10/07/2025. No derivative securities or additional holdings were reported on this form.
Lucid Diagnostics Inc. disclosed that under the agreements governing the sale of its Convertible Notes, the note holders have the collective right to designate one individual to be appointed to the company’s board of directors. This appointment right is subject to certain limitations and to the policies and procedures of the company’s nominating and corporate governance committee. The filing text is brief and focuses solely on the governance right tied to the Convertible Notes.
Lucid Diagnostics, Inc. disclosed a material event on a Form 8-K filed on September 11, 2025. The filing references a preliminary prospectus supplement dated September 9, 2025 and a final prospectus supplement dated September 10, 2025, and attaches a press release announcing the closing as Exhibit 99.1. The document is signed by Dennis McGrath, Chief Financial Officer. The filing indicates a Regulation FD disclosure checkbox and an Inline XBRL cover page data file are included.
The short filing confirms paperwork and a press release related to a completed transaction or offering, but it does not disclose financial terms, the size of any offering, counterparties, or operational impacts. The available content documents the administrative close and supporting prospectus supplements without quantitative details.
Prospectus supplement excerpts for Lucid Diagnostics, Inc. (LUCD) outline a securities offering structure and select pro forma balance sheet items. The underwriting discount is shown as $0.0575 per share totaling $1,437,500, leaving proceeds to the issuer before expenses of $0.9425 per share or $23,562,500. The underwriting allocation lists BTIG LLC: 11,875,000 shares and Maxim Group LLC: 1,250,000 shares toward a 25,000,000-share total. Pro forma capitalization items include Series B and B-1 preferred: 54,419 shares (presented with $54,419), common shares outstanding of 101,826,788, and additional paid-in capital shown as $201,013 (historical) and $224,391 (pro forma). The excerpt contains many table-of-contents entries and procedural disclosures but omits complete line-item values for several fields.
Lucid Diagnostics entered into an underwriting agreement to sell common stock to the public at $1.00 per share, with the underwriters purchasing shares from the company at $0.9425 per share, representing a $0.0575 underwriting discount. The company granted the underwriters a 30-day option to buy up to 3,750,000 additional shares at the public offering price less the underwriting discount. Lucid agreed to reimburse certain underwriting expenses, including legal fees, up to $100,000, and to indemnify the underwriters for specified liabilities under the Securities Act.
The filing cites an underlying registration statement originally filed on November 25, 2022 and declared effective December 6, 2022, and notes a preliminary prospectus supplement dated September 9, 2025 filed that same day; a final prospectus supplement will be filed under Rule 424. The Underwriting Agreement is subject to customary closing conditions, representations, warranties and covenants.
Lucid Diagnostics, Inc. (LUCD) filed a 424B5 prospectus supplement describing an offering of debt securities alongside disclosure of its capital structure as of June 30, 2025. The filing shows 54,419 shares of Series B and Series B-1 convertible preferred stock outstanding and 101,826,788 common shares issued and outstanding. The company reports $201,013 in additional paid-in capital and names BTIG LLC and Maxim Group LLC as underwriters. Several offering-line items (public offering price, underwriting discount, proceeds to issuer, and per-share net tangible book value figures) are present as placeholders or not populated in the provided text.
Lucid Diagnostics director Dennis Matheis reported a purchase of company common stock. The Form 4 discloses a purchase of 100,000 shares on 08/20/2025 at a weighted-average price of $1.0184 per share, with transaction prices ranging from $1.0085 to $1.0286. After the purchase, the reporting person beneficially owned 665,443 shares. The filing indicates the reporting person is a director and the Form 4 was filed by one reporting person. The reporting person authorized Michael A. Gordon to sign the Form 4 by power of attorney.
Lucid Diagnostics Inc. announced it furnished a press release reporting financial results and a business update for the fiscal quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference into this Form 8-K. The company disclosed that the information under Items 2.02 and 7.01, including the exhibit, is furnished and shall not be deemed "filed" under the Exchange Act for purposes of Section 18, nor incorporated by reference in other filings except by specific reference. The filing identifies the registrant as Lucid Diagnostics Inc., trading as LUCD on The Nasdaq Stock Market, and indicates the company qualifies as an emerging growth company.
Lucid Diagnostics (LUCD) is a commercial-stage cancer-prevention diagnostics company selling the EsoGuard test with EsoCheck sampling. For the three and six months ended June 30, 2025 the company recognized $1.16 million and $1.99 million of revenue, respectively, while reporting a net loss attributable to common stockholders of $7.9 million for the quarter and $43.9 million for the six months. Operating activities used $23.0 million of cash in the first half of 2025, leaving $31.1 million of cash and approximately $4.4 million of working capital as of June 30, 2025.
Key balance sheet and financing items include total assets of $38.7 million, stockholders' equity of $7.9 million, and Senior Secured Convertible Notes with $21.975 million face value carried at fair value of $25.3 million (conversion price $1.00; 12% stated interest). Management discloses substantial doubt about going concern absent increased reimbursement, revenue growth or additional financing. Recent developments include two equity raises in March and April 2025 netting ~$31.0 million, an ATM up to $25.0 million, Highmark coverage in New York effective May 26, 2025, MolDx LCD reconsideration (CAC on Sept 4, 2025), multiple peer-reviewed publications, and an $8.0 million NIH R01 award to CWRU investigators.